Kao, Jia-Horng <br/><br/>
All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.  [electronic resource] 

 -  Liver international : official journal of the International Association for the Study of the Liver  10 2016 
 - 1433-41 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1478-3231 
<br/><br/><label>Standard No.: </label>10.1111/liv.13128  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Alanine Transaminase--blood<br/>Antiviral Agents--administration & dosage<br/>Asian People<br/>Carbamates<br/>Double-Blind Method<br/>Drug Resistance, Viral--genetics<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Imidazoles--administration & dosage<br/>International Cooperation<br/>Isoquinolines--administration & dosage<br/>Logistic Models<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Pyrrolidines<br/>RNA, Viral--blood<br/>Sulfonamides--administration & dosage<br/>Sustained Virologic Response<br/>Valine--analogs & derivatives<br/>Viral Load<br/>Viral Nonstructural Proteins--genetics